+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06224673

Study of ARX788 Given by IV for Adults With HER2-low Locally Advanced or Metastatic Breast Cancer

Led by Laura Huppert, MD, BA · Updated on 2026-06-11

36

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ARX788, an antibody-drug conjugate ADC, in patients diagnosed with HER2-low, locally advanced unresectable, or metastatic breast cancer. This phase II trial aims to assess how well ARX788 works by targeting the HER2 protein on cancer cells and delivering a toxin to potentially kill them. The study also explores the safety and effectiveness of an eye toxicity prevention regimen alongside ARX788 treatment. Participants receive ARX788 intravenously over 90 minutes on day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. The study includes two cohorts based on hormone receptor status HRHER2-low and HR-HER2-low. The first five participants also receive topical amiloride eye drops to evaluate eye safety and tolerability. Throughout the study, participants undergo CT, PETCT scans, and blood sample collection. Participants are followed up 30 days after treatment ends and then every 12 weeks for one year. Researchers measure outcomes such as objective response rate, duration of response, disease control, progression-free survival, overall survival, and treatment-emergent adverse events. The study also tracks eye drop adherence, eye pain, and ocular adverse events. Biomarker analyses and patient-reported outcomes are collected to better understand treatment effects and safety.

CONDITIONS

Brief Title

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Research Team

A

Amy Langdon

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here